Allergan Shares Outstanding 2006-2018 | AGN

Allergan shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Allergan shares outstanding for the quarter ending September 30, 2018 were 0.339B, a 1.65% increase year-over-year.
  • Allergan 2017 shares outstanding were 0.334B, a 13.28% decline from 2016.
  • Allergan 2016 shares outstanding were 0.385B, a 4.65% increase from 2015.
  • Allergan 2015 shares outstanding were 0.368B, a 67.41% increase from 2014.
Allergan Annual Shares Outstanding
(Millions of Shares)
2017 334
2016 385
2015 368
2014 220
2013 142
2012 128
2011 127
2010 124
2009 116
2008 118
2007 117
2006 102
2005 120
Allergan Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 339
Q2 2018 339
Q1 2018 335
Q4 2017 334
Q3 2017 334
Q2 2017 335
Q1 2017 335
Q4 2016 385
Q3 2016 393
Q2 2016 396
Q1 2016 395
Q4 2015 368
Q3 2015 394
Q2 2015 393
Q1 2015 290
Q4 2014 265
Q3 2014 264
Q2 2014 175
Q1 2014 175
Q4 2013 174
Q3 2013 134
Q2 2013 132
Q1 2013 130
Q4 2012 128
Q3 2012 128
Q2 2012 126
Q1 2012 128
Q4 2011 127
Q3 2011 127
Q2 2011 126
Q1 2011 126
Q4 2010 124
Q3 2010 124
Q2 2010 124
Q1 2010 123
Q4 2009 116
Q3 2009 117
Q2 2009 119
Q1 2009 118
Q4 2008 118
Q3 2008 118
Q2 2008 118
Q1 2008 117
Q4 2007 117
Q3 2007 117
Q2 2007 117
Q1 2007 117
Q4 2006 102
Q3 2006 116
Q2 2006 102
Q1 2006 117
Q4 2005 120
Q3 2005 118
Q2 2005 121
Q1 2005 124
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $53.085B $15.941B
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $22.626B 6.93
Mylan (MYL) United Kingdom $18.006B 7.41
Bausch Health Cos (BHC) Canada $8.859B 6.41
Dr Reddy's Laboratories (RDY) India $5.791B 23.13
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.571B 4.29
Supernus Pharmaceuticals (SUPN) United States $2.296B 21.75
Amphastar Pharmaceuticals (AMPH) United States $0.953B 103.35
Akorn (AKRX) United States $0.860B 0.00
Homology Medicines (FIXX) United States $0.769B 0.00
Assembly Biosciences (ASMB) United States $0.628B 0.00
CymaBay Therapeutics (CBAY) United States $0.574B 0.00
Corium (CORI) United States $0.459B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.455B 0.00
Voyager Therapeutics (VYGR) United States $0.405B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.296B 0.00
Teligent (TLGT) United States $0.137B 0.00
Sol-Gel Technologies (SLGL) Israel $0.132B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.093B 0.00
Aevi Genomic Medicine (GNMX) United States $0.071B 0.00
Acasti Pharma (ACST) Canada $0.057B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.051B 0.00
Evoke Pharma (EVOK) United States $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.029B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00